



Formulary Changes Announced

Third quarter changes to the Independent Health Drug formularies are summarized below and currently in effect unless otherwise noted.

NPG/NPB - Non-Preferred Generic/Brand
 PG/PB - Preferred Generic/Brand
 NF – Non-Formulary
 SP - Specialty Pharmacy
 PA - Prior Authorization
 ST – Step Therapy

QL – quantity Limits
 SC – subcutaneous
 IM - intramuscular
 inj – injection
 tab – tablet
 cap – capsule
 ophm- ophthalmic

soln – solution
 susp – suspension
 MDI-metered-dose inhalation aerosol
 ODT – orally-disintegrating tablet
 LA-available only at certain pharmacies
 G- Generic (T2) for Medicare

Changes to Drug Formulary I (DF1), FEHB Formulary, and Pharmacy Benefit Dimensions Formulary		
Medications Added to Formulary 10/1/2023	Medications Non-Formulary 10/1/2023	Changes to Formulary 10/1/2023
adalimumab-adaz SC inj PB, PA, SP (8/15/2023) Akeega (niraparib/abiraterone) tab- NPB, PA, SP, LA Hadlima (adlimumab) SC inj- PB, PA, SP (8/15/2023) Lodoco (colchicine) tab NPB, PA Ngenla (somatrogon-ghla) SC inj- TBD Opill (norgestrel) tab- PB, ACA \$0 Opvee (nalmefene) nasal spray PB RiVive (naloxone) nasal spray PB Vanflyta (quizartinib) tab NPB, PA, SP, LA Veozah (fezolinetant) tab NPB, PA Xpovio NPB PA Zurzuvae (zuranolone) cap NPB, PA	Inpefa (sotagliflozin) tab Litalo (ritlecitinib) cap (block as cosmetic) Miebo (perfluorohexyloctane) ophm soln Sufflave (PEG 3350/Na2SO4/KCl/MgSO4/NaCl) powder for oral soln Vevye (cyclosporine) ophm soln Xdemvy (lotilaner) ophm soln Yufflyma (adalimumab-aaty) SC inj zolpidem 7.5 mg cap	albendazole remove PA azathioprine 75mg and 100mg tab from T2 to NF (1/1/2024) Azelex 20% cream move from T2 to T3 (1/1/2024) Cleocin 100mg vaginal suppository from T2 to NF (1/1/2024) cyclobenzaprine 7.5 mg tablets from T1 to NF (1/1/2024) ertapenem IV remove PA (9/1/2023) leflunomide tab remove PA (10/1/2023) Move from T1 to T3: (1/1/2024) -cephalexin cap 750 mg -cefixime cap 400 mg -cefixime oral susp 100 mg/5ml -cefixime oral susp 200 mg/5ml -erythromycin ethylsuccinate tab 400mg -amoxicillin/clavulanate tab ER 12hr 1000-62.5 mg nitrofurantoin macrocrystal cap remove max age 64yo (9/1/2023) pretomanid remove PA rifabutin remove PA

Changes to Drug Formulary II (DF2), Drug Formulary III (DF3), and Essential Plan Formulary (EPF)		
Medications Added to Formulary 10/1/2023	Medications Non-Formulary 10/1/2023	Changes to Formulary 10/1/2023
adalimumab-adaz SC inj PB, PA, SP (8/15/2023) Akeega (niraparib/abiraterone) tab- NPB, PA, SP, LA Hadlima (adlimumab) SC inj- PB, PA, SP (8/15/2023) Lodoco (colchicine) tab NPB, PA Ngenla (somatrogon-ghla) SC inj- TBD Opill (norgestrel) tab- PB, ACA \$0 Opvee (nalmefene) nasal spray PB RiVive (naloxone) nasal spray PB Vanflyta (quizartinib) tab NPB, PA, SP, LA Veozah (fezolinetant) tab NPB, PA Xpovio NPB PA Zurzuvae (zuranolone) cap NPB, PA	Inpefa (sotagliflozin) tab Litalo (ritlecitinib) cap (block as cosmetic) Miebo (perfluorohexyloctane) ophm soln Ngenla (somatrogon-ghla) SC inj- TBD Sufflave (PEG 3350/Na2SO4/KCl/MgSO4/NaCl) powder for oral soln Vevye (cyclosporine) ophm soln Xdemvy (lotilaner) ophm soln Yufflyma (adalimumab-aaty) SC inj zolpidem 7.5 mg cap	albendazole remove PA amoxicillin/clavulanate tab ER 12hr 1000-62.5 mg move from T1 to T3 (1/1/2024) azathioprine 75mg and 100mg tab from T2 to NF (1/1/2024) Cleocin 100mg vaginal suppository from T3 to NF (1/1/2024) cyclobenzaprine 7.5 mg tablets from T1 to NF (1/1/2024) ertapenem IV remove PA (9/1/23) leflunomide tab remove PA (10/1/2023) Move from T2 to T3: (1/1/2024) -cefixime cap 400 mg -cefixime oral susp 100 mg/5ml -cefixime oral susp 200 mg/5ml -erythromycin ethylsuccinate tab 400mg nitrofurantoin macrocrystal cap remove max age 64yo (9/1/2023) pretomanid remove PA rifabutin remove PA

Changes to Child Health Plus Formulary		
Medications Added to Formulary 10/1/2023	Medications Non-Formulary 10/1/2023	Changes to Formulary 10/1/2023
adalimumab-adaz SC inj PB, PA (8/15/2023) Hadlima (adlimumab) SC inj- PB, PA (8/15/2023) Opill (norgestrel) tab- PB, ACA \$0 Opvee (nalmefene) nasal spray PB RiVive (naloxone) nasal spray PB	Akeega (niraparib/abiraterone) tab Inpefa (sotagliflozin) tab Litalo (ritlecitinib) cap (block as cosmetic) Lodoco (colchicine) tab Miebo (perfluorohexyloctane) ophm soln Ngenla (somatrogon-ghla) SC inj Sufflave (PEG 3350/Na2SO4/KCl/MgSO4/NaCl) powder for oral soln Vanflyta (quizartinib) tab Veozah (fezolinetant) tab Vevye (cyclosporine) ophm soln Xdemvy (lotilaner) ophm soln Yufflyma (adalimumab-aaty) SC inj zolpidem 7.5 mg cap Zurzuvae (zuranolone) cap	albendazole remove PA azathioprine 75mg and 100mg tab from T2 to NF (1/1/2024) Cleocin 100mg vaginal suppository from T2 to NF (1/1/2024) cyclobenzaprine 7.5 mg tablets from T1 to NF (1/1/2024) ertapenem IV remove PA (9/1/23) Humira NF (10/1/2023) leflunomide tab remove PA (10/1/2023) nitrofurantoin macrocrystal cap remove max age 64yo (9/1/2023) pretomanid remove PA rifabutin remove PA Suboxone brand and Zubsolv from T2 to NF (8/9/2023)

Changes to Medicare Formulary		
Medications Added to Formulary 10/1/2023	Medications Non-Formulary 10/1/2023	Changes to Formulary 10/1/2023
Abrysvo (RSV vaccine) IM inj- PB, AL Akeega (niraparib/abiraterone) tab- NPB, PA, SP, LA adalimumab-adaz SC inj PB (9/1/2023) Hadlima (adalimumab) SC inj- PB (9/1/2023) Lodoco (colchicine) tab NPB, PA Miebo (perfluoroheptyloctane) ophm soln NB, PA Ngenla (somatrogon-ghla) SC inj- TBD Opvee (nalmefene) nasal spray PB Vanflyta (quizartinib) tab NPB, PA, SP, LA Veozah (fezolinetant) tab NPB, PA Zurzuvae (zuranolone) cap NPB, PA	Inpefa (sotagliflozin) tab Litfulo (ritilecitinib) cap Ngenla (somatrogon-ghla) SC inj Opill (norgestrel) tab- (block as OTC) RiVive (naloxone) nasal spray PB (block as OTC) Suflave (PEG 3350/Na2SO4/KCl/MgSO4/NaCl) powder for oral soln Vevye (cyclosporine) ophm soln Xdemvy (lotilaner) ophm soln Yuflyma (adalimumab-aaty) SC inj zolpidem 7.5 mg cap	Amjevita (adalimumab) SC inj NF (1/1/2024)

Policy updates of drugs with new indications

Drugs with new indications:

Brand name	Generic name	New indication(s)	Coverage changes
Abrilada	adalimumab-afzb	hidradenitis suppurativa	None
Amjevita	adalimumab-atto	uveitis	None
Ayvakit	avapritinib	indolent systemic mastocytosis	Policy updates
Bylvay	odevixibat	cholestatic pruritus in Alagille syndrome	Policy updates
Cyltezo	adalimumab-adbm	uveitis	None
Ervebo	Ebola Zaire vaccine, live	indication now down to 12 months of age	None
Ezallor	rosuvastatin	all rosuvastatin indications	None
Hadlima	adalimumab-bwwd	hidradenitis suppurativa	None
Hadlima	adalimumab-bwwd	uveitis	None
Injectafer	ferric carboxymaltose	iron deficiency in HF to improve exercise capacity	Policy updates
Jardiance	empagliflozin	type 2 diabetes down to 10 years of age	AL changes
Leqvio	inclisiran	wording changed to primary hyperlipidemia	Policy updates
Liletta	levonorgestrel IU	heavy menstrual bleeding	None
Linzess	linaclotide	pediatric functional constipation	None
Lonsurf	tipiracil/trifluridine	mCRC can be alone or with bevacizumab	Policy updates
Lynparza	olaparib	w/abiraterone + steroid for BRCA-mutated mCRPC	Policy updates
Nucynta	tapentadol	pain down to 6 years of age	AL changes as necessary
Prevymis	letermovir	CMV prophylaxis in high-risk kidney transplant	Policy updates
Spy Agent Green	indocyanine green	lymphatic mapping in adults with breast cancer	None
Synjardy	empagliflozin/metformin	type 2 diabetes down to 10 years of age	AL changes
Talzenna	talazoparib	w/enzalutamide for HRR-mutated mCRPC	Policy updates
Triumeq	ABC/dolutegravir/3TC	lower limits 3 months of age/6 kg	None
Veklury	remdesivir	COVID-19 in pts w/renal impairment, including dialysis	None

Medical (effective 10/1/2023):

- Abrysvo** (respiratory syncytial virus vaccine) intramuscular injection- Medical, AL
- Balfaxar** (prothrombin complex concentrate, human-lans)- Medical
- Beyfortus** (nirsevimab-alip) intramuscular injection- Medical, AL w/PA
- Brixadi** (buprenorphine) extended-release subcutaneous injection-Medical
- Columvi** (glofitamab-gxbm) intravenous injection- Medical, PA
- Cyfundus** (anthrax vaccine adsorbed, adjuvanted)- is not likely to be commercialized outside of national stockpiling
- Elfabrio** (pegunigalsidase alfa-iwxj) intravenous injection- Medical, PA, SP, LA
- Elevidys** (delandistrogene moxeparvec-rokl) suspension for intravenous infusion- Block w/policy – no clinical data (commercial and state plans); Medical, PA, SP, LA (Medicare)
- Epkinly** (epcoritamab-bysp) subcutaneous injection- Medical, PA
- Elrexio** (elranatamab-bcmm) subcutaneous injection- Medical, PA
- Izervay** (avacincaptad pegol) intravitreal injection- Medical, PA
- Lantidra** (donislecil-jujn) suspension for hepatic portal vein infusion- Medical, PA
- Leqembi** (Icanemab-irmb) intravenous injection- Block – inconclusive clinical evidence of benefit, inconclusive benefit-to-risk profile; Medical, PA (Medicare, FEHB, Medicaid)
- Posluma** (flotufolastat F-18)- Medical
- Roctavian** (valoctocogene roxaparvec-rvox) intravenous infusion- Medical, PA
- Rystiggo** (rozanolixizumab-noli) subcutaneous infusion- Medical, PA
- Talvey** (talquetamab-tgvs) subcutaneous injection- Medical, PA
- Vivimusta** (bendamustine) intravenous injection- Medical, PA
- Vyjuvek** (beremagene geperpavec-svdt) biological suspension plus excipient gel- Medical, PA
- Vyvgart Hytrulo** (efgartigimod alfa/hyaluronidase-qvfc) subcutaneous injection- Medical, PA
- Xacduro** (sulbactam/durlobactam) intravenous injection- Medical, PA
- Ycanth** (cantharidin) topical solution- Medical, PA

New generics:

Brands now non-formulary unless otherwise indicated. For Medicaid, medical drugs will be covered as Commercial unless otherwise specified below.

Brand name	Generic name	Generic tier placement/utilization management			
		Commercial (DF1)/ FEHB	Exch (DF2)/Small (DF3)/EBP	Child Health Plus	Medicare Indiv/PDP
Celontin	methsuximide	T1	T1	NF	T2/T1
Prezista	darunavir	T1	T1	T1	T5/T1
Indocin	indomethacin suppositories	NF	NF	NF	NF/NF
Kombiglyze XR	saxagliptin/metformin	NF	NF	NF	NF/NF
Onglyza	saxagliptin	NF	NF	NF	NF/NF
Symbicort	Breyna (true generic)	TBD	TBD	TBD	TBD/TBD